We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Antibodies Against Rabies Detected in Human Dried Blood Spots

By LabMedica International staff writers
Posted on 03 Nov 2020
Print article
Image: Serological test performed at the rabies laboratory. The Bio-Rad Platelia Rabies II ELISA kit is one of the diagnostic assays that are routinely conducted for the determination of antibodies against the rabies virus (Photo courtesy of Korean Animal and Plant Quarantine Agency).
Image: Serological test performed at the rabies laboratory. The Bio-Rad Platelia Rabies II ELISA kit is one of the diagnostic assays that are routinely conducted for the determination of antibodies against the rabies virus (Photo courtesy of Korean Animal and Plant Quarantine Agency).
Rabies is a viral disease that causes inflammation of the brain in humans and other mammals. Early symptoms can include fever and tingling at the site of exposure. Although preventable by vaccination for more than a century, rabies virus still causes numerous fatalities every year.

Rabies can be difficult to diagnose because, in the early stages, it is easily confused with other diseases or with aggressiveness. The reference method for diagnosing rabies is the fluorescent antibody test (FAT), an immunohistochemistry procedure, which is recommended. The RT-PCR assays proved to be a sensitive and specific tool for routine diagnostic purposes.

Virologists at the Erasmus University Medical Center (Rotterdam, The Netherlands) evaluated the use of human dried blood samples (DBS) for rabies serology and analyzed 99 pre- or post-vaccination serum and DBS samples with a fluorescent antibody virus neutralization test (FAVNt), which is the gold standard to detect protective antibody levels, and the Platelia Rabies II enzyme-linked immunosorbent assay (ELISA) (Bio-Rad, Hercules, CA, USA).

The scientists reported that the DBS-ELISA showed a sensitivity of 86.5% (95% CI 76.6–93.3) and a specificity of 96.0% (95% CI 79.7–99.9) compared to the gold standard serum-FAVNt. The sensitivity increased to 91.6% (95% CI 82.5–96.8) when the DBS-ELISA was compared with serum-ELISA. Moreover, the specificity increased to 100% (95% CI 87.7–100.0). The antibody concentrations measured in DBS eluates and sera correlated significantly when measured with either FAVNt or Platelia-II ELISA.

The authors concluded that both the FAVNt and Platelia-II ELISA demonstrate an acceptable performance on DBS, providing opportunities for rabies serology in remote areas. This technique could drastically ease studies evaluating (novel) rabies vaccination strategies and monitoring persisting immunity in humans at risk, living in rabies endemic regions. The reported high specificities provide confidence that unprotected individuals will rarely be missed. Therefore, the DBS is a promising sampling technique for evaluations of vaccination strategies and monitoring persisting immunity after vaccination in populations at risk for rabies. The study was published on October 13, 2020 in the journal PLOS Neglected Tropical Diseases.



Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
Unstirred Waterbath
HumAqua 5

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.